SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.

Thomas W. Flaig; Catherine M. Tangen; Siamak Daneshmand; Ajjai Shivaram Alva; Seth P. Lerner; M. Scott Lucia; David James McConkey; Dan Theodorescu; Amir Goldkorn; Matthew I. Milowsky; Richard Carlton Bangs; Gary R. MacVicar; Bruno R. Bastos; Daniel Gustafson; Melissa Plets; Ian Murchie Thompson

doi:10.1200/JCO.2019.37.15_SUPPL.4506

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.

Thomas W. Flaig
, Catherine M. Tangen
, Siamak Daneshmand
, Ajjai Shivaram Alva
, Seth P. Lerner
, M. Scott Lucia
, David James McConkey
, Dan Theodorescu
, Amir Goldkorn
, Matthew I. Milowsky
, Richard Carlton Bangs
, Gary R. MacVicar
, Bruno R. Bastos
, Daniel Gustafson
, Melissa Plets
, Ian Murchie Thompson

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1200/JCO.2019.37.15_SUPPL.4506
State	Published - May 26 2019

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1200/JCO.2019.37.15_SUPPL.4506License: Unspecified

Cite this

Flaig, T. W., Tangen, C. M., Daneshmand, S., Alva, A. S., Lerner, S. P., Lucia, M. S., McConkey, D. J., Theodorescu, D., Goldkorn, A., Milowsky, M. I., Bangs, R. C., MacVicar, G. R., Bastos, B. R., Gustafson, D., Plets, M., & Thompson, I. M. (2019). SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. Journal of Clinical Oncology, 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.4506

Flaig, TW, Tangen, CM, Daneshmand, S, Alva, AS, Lerner, SP, Lucia, MS, McConkey, DJ, Theodorescu, D, Goldkorn, A, Milowsky, MI, Bangs, RC, MacVicar, GR, Bastos, BR, Gustafson, D, Plets, M & Thompson, IM 2019, 'SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.', Journal of Clinical Oncology, vol. 37. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.4506

@article{b10dae5380ee483ebad2c6cd149ee33c,

title = "SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.",

author = "Flaig, \{Thomas W.\} and Tangen, \{Catherine M.\} and Siamak Daneshmand and Alva, \{Ajjai Shivaram\} and Lerner, \{Seth P.\} and Lucia, \{M. Scott\} and McConkey, \{David James\} and Dan Theodorescu and Amir Goldkorn and Milowsky, \{Matthew I.\} and Bangs, \{Richard Carlton\} and MacVicar, \{Gary R.\} and Bastos, \{Bruno R.\} and Daniel Gustafson and Melissa Plets and Thompson, \{Ian Murchie\}",

note = "4506 Background: Both dose-dense Methotrexate-Vinblastine-Adriamycin/doxorubicin-Cisplatin (ddMVAC) and Gemcitabine-Cisplatin (GC) are accepted neoadjuvant regimens for muscle-invasive bladder cancer (BC). We investigated COXEN, a gene expression model, as a predictive biomarker. Methods: Eligibility included Stage cT2-T4a N0 M0, urothelial BC (mixed histology allowed), ≥ 5 mm of viable tumor, cisplatin eligible, with plan for cystectomy.",

year = "2019",

month = may,

day = "26",

doi = "10.1200/JCO.2019.37.15\_SUPPL.4506",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.

AU - Flaig, Thomas W.

AU - Tangen, Catherine M.

AU - Daneshmand, Siamak

AU - Alva, Ajjai Shivaram

AU - Lerner, Seth P.

AU - Lucia, M. Scott

AU - McConkey, David James

AU - Theodorescu, Dan

AU - Goldkorn, Amir

AU - Milowsky, Matthew I.

AU - Bangs, Richard Carlton

AU - MacVicar, Gary R.

AU - Bastos, Bruno R.

AU - Gustafson, Daniel

AU - Plets, Melissa

AU - Thompson, Ian Murchie

N1 - 4506 Background: Both dose-dense Methotrexate-Vinblastine-Adriamycin/doxorubicin-Cisplatin (ddMVAC) and Gemcitabine-Cisplatin (GC) are accepted neoadjuvant regimens for muscle-invasive bladder cancer (BC). We investigated COXEN, a gene expression model, as a predictive biomarker. Methods: Eligibility included Stage cT2-T4a N0 M0, urothelial BC (mixed histology allowed), ≥ 5 mm of viable tumor, cisplatin eligible, with plan for cystectomy.

PY - 2019/5/26

Y1 - 2019/5/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4506

U2 - 10.1200/JCO.2019.37.15_SUPPL.4506

DO - 10.1200/JCO.2019.37.15_SUPPL.4506

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.

Disciplines

Access to Document

Other files and links

Cite this